In fact, the findings of the Dafni et al. meta-analysis support the superiority of pembrolizumab, particularly in the management of NSCLC patients with a PD-L1 expression level of 50% or higher[42]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.